Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Indonesian Journal of Cancer Jurnal ARSI : Administrasi Rumah Sakit Indonesia Jurnal Ekonomi Kesehatan Indonesia
Dody Ranuhardy, Dody
Unknown Affiliation
Decision Sciences, Operations Research & Management Economics, Econometrics & Finance Health Professions Medicine & Pharmacology Public Health Social Sciences

Published : 5 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 5 Documents
Search

 1 
Efficacy and Safety of In-Asia-Manufactured rhG-CSF 300 mcg As Primary Prophylaxis for Prevention of CHOP Chemotherapy-induced Severe Neutropenia in Elderly Patients with Lymphoma Non-Hodgkin Reksodiputro, Harryanto; Djoerban, Zubairi; Tambunan, Karmel L.; Sudoyo, Aru W.; Widjanarko, Abidin; Atmakusuma, Djumhana; Syafei, Syafrizal; Prayogo, Nugroho; Hukom, Ronald; Ranuhardy, Dody; Jack, Zakifman; Harsal, Asrul; -, Noorwati S; Karsono, Bambang; Effendi, Shufrie; Tadjoedin, Hilman
Indonesian Journal of Cancer Vol 3, No 1 (2009): Jan - Mar 2009
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (790.74 KB)

Abstract

Penelitian open-label, non-komparatif ini dilakukan untuk mengevaluasi efektivitas dan keamanan recombinant human G-CSF produksi Asia sebagai profilaksis primer dalam pencegahan neutropenia derajat berat pada pasien usia lanjut (>60 tahun) dengan limfoma non-Hodgkin (LNH) derajat sedang dan lanjut (stadium II,III,IV) yang mendapat terapi CHOP (siklofosfamid, doksorubisin, vinkristin). Profilaksis primer recombinant human G-CSF (rhG-CSF) produksi Asia dapat mengurangi median durasi neutropenia derajat 4 pada siklus sitostatistika ke-1 dan ke-2 menjadi tiga hari, sementara median durasi neutropenia derajat 3 pada siklus sitostistika ke-1 menjadi dua hari dan pada siklus sitostatistika ke-2 menjadi dua setengah hari, dari median durasi neutropenia grade 4 dan grade 3 tanpa G-CSF, yaitu empat dan lima hari berurutan. Febrile neutropenia ditemukan pada 7 pasien yang mendapat rhG-CSF produksi Asia (24.1%), lebih rendah jika dibandingkan studi tanpa rhG-CFS (31.3-34% FN). Tiga pasien mendapat rhG-CSF produksi Asia (10,3%) dirawat inap akibat febrile neutropenia, lebih rendah jika dibandingkan rawat inap pada studi tanpa rhG-CSF (24-28%). Kejadian yang tidak diinginkan terbanyak adalah mual dan muntah yang terjadi pada 9 (31%) pasien. Sebagai kesimpulan, penggunaan rhG-CSF produksi Asia untuk profilaksis primer pada pasien LNH usia lanjut yang mendapat regimen CHOP dapat mengurangi durasi neutropenia, mengurangi kejadian febrile neutropenia, dan angka rawat inap akibat febrile neutropenia.Kata kunci : Efektivitas, keamanan, G-CSF, LNH pada usia lanjut
Stem Cell Therapy in Adult Hematologic Malignancy Ranuhardy, Dody
Indonesian Journal of Cancer Vol 3, No 5 (2009): Workshops 2009
Publisher : "Dharmais" Cancer Center Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

https://www.scribd.com/doc/45501207/Stem-Cell-Therapy-in-Adult-Hematologic-Malignancy
The Role of Febrile Neutropenia Guideline’s Implementation on Mortality Rate in Dharmais Hospital-National Cancer Center Ranuhardy, Dody
Indonesian Journal of Cancer Vol 12, No 3 (2018): July-September
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (760.775 KB) | DOI: 10.33371/ijoc.v12i3.612

Abstract

Introduction: Febrile neutropenia have a high morbidity and mortality impact for the patient. The mortality rate of febrile neutropenia in 2002 was 38.8%, while it was 27.3% in 2009. The difference in mortality rates could be caused by several factors such as availability of the Neutropenic Fever Management Guidelines in 2006, in addition to infrastructure, human resources and equipment. This study aims to determine the role of guideline availibility and other factors to cancer mortality rate in the immunocompromised isolation room of Dharmais Hospital. Methods: This study was a cross-sectional retrospective study which investigate mortality rates and compare with adherence to febrile neutropenia guidelines for the period 2008-2012. Data were taken from the patient's medical record file, and then analysed using univariate and bivariate analysis. Results: The mortality rate in the period 2008-2012 was 20.7%. The correlation between age, sex, and degree of risk factor on mortality was not significantly different (p=0,409, p=0,404, and p=0,324). The proportion of deaths was higher in patients borne by third parties (26.8%) than in the case of personal (10%) although not statistically significant (p=0,065). From the three types of adherence, only one had a significant effect of adherence to treatment flow (p=0,033). Conclusions: The availibility of management guideline can reduce mortality rate of febrile neutropenia even though from the three types of adherence, only one had a significant effect of adherence to treatment flow (p=0,033).
Effect of Febrile Neutropenia Guideline’s Implementation on Death Rate in Dharmais Cancer Center Hospital Ranuhardy, Dody
Jurnal ARSI : Administrasi Rumah Sakit Indonesia Vol. 4, No. 3
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Febrile neutropenia may have a high morbidity and mortality impact for the patient. The death rate of febrile neutropenia in 2002 was 38.8%, while in 2009 was 27.3%. The difference in mortality rates could caused by several factors such as availability of the Neutropenic Fever Management Guidelines in 2006, in addition to infrastructure, human resources and equipment. This study aims to determine the effect of the availability of the guideline and other factors to cancer mortality rate in the compromised immune isolation room of Dharmais Hospital. This study is a cross-sectional retrospective study which investigate mortality rates and compare with adherence to febrile neutropenia guidelines for the period 2008-2012. Data were taken from the patient's medical record file, then analyzed using univariate and bivariate analysis. The mortality rate in the period 2008-2012 was 20,7%. The effect of age, sex, and degree of risk factor on mortality was not significantly different (p=0,409, p=0,404, and p=0,324). The proportion of deaths was higher in patients borne by third parties (26.8%) than in the case of personal (10%) although not statistically significant (p=0,065). Of the three types of adherence, only one had a significant effect of adherence to treatment flow (p=0,033).
Evaluasi Ekonomi Parsial antara Pemberian Terapi Rivaroxaban dan Terapi Kombinasi (Unfractionated Heparin + Warfarin) untuk Pengobatan Trombosis Vena Dalam pada Pasien Kanker di Rumah Sakit Kanker Dharmais Syari, Wirda; Nadjib, Mardiati; Ranuhardy, Dody
Jurnal Ekonomi Kesehatan Indonesia Vol. 5, No. 1
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Based on previous studies, rivaroxaban therapy has several advantages compared to combination therapy (UFH+warfarin) for the treatment of deep vein thrombosis (DVT). However, the use of rivaroxaban in Dharmais Cancer Hospital is still low. This partial economic evaluation study aims to analyze cost and outcome of rivaroxaban therapy and combination therapy (UFH+warfarin) for DVT treatment in cancer patients at the Dharmais Cancer Hospital during 2016 – 2018. Data collection was done using cohort-retrospective and individual unit of analysis. Due to limited number of patient treated with rivaroxaban therapy within 3-6 months, we estimated the cost and outcome related to patients who were successfully treated in one month. The outcome was the intermediate outcome, i.e length of stay, recovery, and the occurrence of bleeding. The cost was calculated based on hospital perspective including drugs, laboratory tests, procedures, as well as the administrative and accommodation costs. The results showed that patients with rivaroxaban therapy were not admitted to inpatient care, 40% of patients were recovered from DVT, and none of the patients experienced bleeding. The average cost of rivaroxaban therapy to reach the expected outcome was Rp 8,824,791.00. The study also showed that patients with combination therapy (UFH+warfarin) had a hospital length of stay between 8 to 14 days, 46% of patients were recovered from DVT, and none of the patients experienced bleeding. The average cost of combination therapy (UFH+warfarin) to reach the expected outcome was Rp 13,201,698.00.
Co-Authors Abidin Widjanarko Andalucia, Rizka Arif Abdillah Aru W. Sudoyo Asrul Harsal, Asrul Bambang Karsono Djumhana Atmakusuma, Djumhana EVLINA SUZANNA, EVLINA Hadisantoso, Dwi W Harryanto Reksodiputro, Harryanto HILMAN TADJOEDIN, HILMAN Karmel L. Tambunan Nadjib, Mardiati Noorwati S -, Noorwati S Nugroho Prayogo Ronald Hukom Sari, Resti M Shufrie Effendi, Shufrie Syafrizal Syafei, Syafrizal Wirda Syari Zakifman Jack, Zakifman Zubairi Djoerban